Profile
| Metric | Value |
|---|---|
| Full Name | CytomX Therapeutics, Inc. |
| Ticker | NASDAQ: CTMX |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | cytomx.com |
| Employees | 119 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $4.25 | |
| Price, 1D Change | -0.23% | |
| Market Cap | $720M | |
| - | ||
| PE Ratio | 10.16 | |
| Beta | 2.22 | |
| Revenue | $138M | |
| Revenue, 1Y Change | +36.45% | |
| EPS | $0.38 | |
| EPS, 1Y Change | +4,984.42% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $0.38 | |
| EPS Estimate | -$0.02 | |
| EPS Est. Change | -106.41% | |
| Revenue | $138.10M | |
| Revenue Estimate | $83.16M | |
| Revenue Est. Change | -39.78% | |
| Current Price | $4.25 | |
| Price Target | - | $6.50 |
| Price Tgt. Change | - | +52.94% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$0.05 | -$0.01 | +84.60% | |
| $0.03 | $0.38 | +1,002.93% | |
| -$0.02 | N/A | -106.41% | |
| -$0.36 | N/A | -196.33% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $95.62M | $101.21M | +5.85% | |
| $115.72M | $138.10M | +19.34% | |
| $83.16M | N/A | -39.78% | |
| $30.73M | N/A | -77.75% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +300.94% | |
| Price, 3Y | +165.62% | |
| Market Cap, 1Y | +748.12% | |
| Market Cap, 3Y | +579.57% | |
| Revenue, 1Y | +36.45% | |
| Revenue, 3Y | +270.13% | |
| EPS, 1Y | +4,984.42% | |
| EPS, 3Y | +120.82% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $4.25 | |
| SMA 200 | $2.49 | |
| SMA 200 vs Price | -41.51% | |
| SMA 50 | $3.93 | |
| SMA 50 vs Price | -7.49% | |
| Beta | 2.22 | |
| ATR | $0.27 | |
| 14-Day RSI | 55.55 | |
| 10-Day Volatility | 53.45% | |
| 1-Year Volatility | 160.92% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $138.10M | |
| EPS | $0.38 | |
| Gross Profit | $136.34M | |
| Gross Margin | 98.72% | |
| Operating Profit | $25.00M | |
| Operating Margin | 18.10% | |
| Net Income | $31.87M | |
| Net Margin | 23.08% | |
| EBITDA | $26.76M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.00 | |
| 1.25 | ||
| 1.25 | ||
| - | ||
| 5 | ||
| -2.38 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 10.16 | |
| 6.34 | ||
| 6.71 | ||
| 23.83 | ||
| N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | -$456.00K | |
| $38.05M | ||
| $122.64M | ||
| $107.31M | ||
| $123.10M | ||
| $85.77M | ||
| Total Debt | $9.39M | |
| $5.15M | ||
| $1.09M |
Expenses
| Metric | Date | Value |
|---|---|---|
| $113.11M | ||
| $113.11M | ||
| $1.77M | ||
| $29.73M | ||
| $1.77M | ||
| $0.00 | ||
| $224.00K |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| -$86.23M | ||
| $99.70M | ||
| $7.52M | ||
| Capex | $310.00K | |
| -$86.54M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| HC Wainwright & Co. | → | |
| Barclays | → | |
| Cantor Fitzgerald | ||
| Oppenheimer | ||
| HC Wainwright & Co. | → | |
| Piper Sandler | → | |
| HC Wainwright & Co. | → | |
| Piper Sandler | → | |
| HC Wainwright & Co. | → | |
| HC Wainwright & Co. | → |
Analyst sentiment
Institutional ownership
Screeners with CTMX
Data Sources & References
- CTMX Official Website www.cytomx.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1501989/000119312525269477/0001193125-25-269477-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1501989/000095017025034575/0000950170-25-034575-index.htm
- CTMX Profile on Yahoo Finance finance.yahoo.com/quote/CTMX
- CTMX Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/ctmx
FAQ
What is the ticker symbol for CytomX Therapeutics, Inc.?
The ticker symbol for CytomX Therapeutics, Inc. is NASDAQ:CTMX
Does CytomX Therapeutics, Inc. pay dividends?
No, CytomX Therapeutics, Inc. does not pay dividends
What sector is CytomX Therapeutics, Inc. in?
CytomX Therapeutics, Inc. is in the Healthcare sector
What industry is CytomX Therapeutics, Inc. in?
CytomX Therapeutics, Inc. is in the Biotechnology industry
What country is CytomX Therapeutics, Inc. based in?
CytomX Therapeutics, Inc. is headquartered in United States
When did CytomX Therapeutics, Inc. go public?
CytomX Therapeutics, Inc. initial public offering (IPO) was on October 8, 2015
Is CytomX Therapeutics, Inc. in the S&P 500?
No, CytomX Therapeutics, Inc. is not included in the S&P 500 index
Is CytomX Therapeutics, Inc. in the NASDAQ 100?
No, CytomX Therapeutics, Inc. is not included in the NASDAQ 100 index
Is CytomX Therapeutics, Inc. in the Dow Jones?
No, CytomX Therapeutics, Inc. is not included in the Dow Jones index
When was CytomX Therapeutics, Inc. last earnings report?
CytomX Therapeutics, Inc.'s most recent earnings report was on November 6, 2025
When does CytomX Therapeutics, Inc. report earnings?
The next expected earnings date for CytomX Therapeutics, Inc. is March 5, 2026